CRVO: CervoMed, Inc.
About
CervoMed, Inc. is a clinical stage biotechnology company. It engages in the business of advancing CNS focused therapeutics to benefit patients with a range of degenerative diseases of the brain. The company is currently developing neflamapimod, an investigational orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha. The company was founded in1995 and is headquartered in Boston, MA.
Current Value
$10.151 Year Return
Current Value
$10.151 Year Return
Key Details
Market Cap
$83.20M
P/E Ratio
-6.16
1Y Stock Return
2.86%
1Y Revenue Growth
559.46%
Dividend Yield
0.00%
Price to Book
1.8
Strategies that include CRVO
Stock's related to CRVO
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| GRAL | 29.75% | $459.22M | -13.00% | 0.00% |
| PRLB | 26.42% | $907.12M | +1.96% | 0.00% |
| MG | 23.42% | $12.29B | -21.35% | 4.47% |
| K | 22.39% | $27.77B | +52.50% | 2.79% |
| ALG | 21.89% | $2.30B | +4.01% | 0.55% |
| NEUE | 21.83% | $40.93M | -34.13% | 0.00% |
| DKNG | 21.68% | $21.07B | +13.03% | 0.00% |
| RMBL | 21.67% | $215.76M | -1.61% | 0.00% |
| FUN | 21.64% | $4.60B | -16.51% | 0.00% |
| GEV | 21.64% | $93.72B | +159.05% | 0.00% |
| HIPO | 21.49% | $708.87M | +243.57% | 0.00% |
| SKLZ | 21.42% | $93.29M | -16.05% | 0.00% |
| SIGA | 21.18% | $446.99M | +29.99% | 0.00% |
| WMS | 21.18% | $10.01B | +9.46% | 0.46% |
| MOG.A | 21.12% | $6.98B | +60.59% | 0.51% |
| GLRE | 20.70% | $510.30M | +29.88% | 0.00% |
| VTS | 20.57% | $813.63M | +15.04% | 7.40% |
| ARM | 20.37% | $139.85B | +126.83% | 0.00% |
| GRPN | 20.37% | $353.14M | -10.75% | 0.00% |
| MG | 20.28% | $282.81M | +42.06% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| BATRK | -0.01% | $2.51B | +13.03% | 0.00% |
| VSTM | -0.03% | $176.25M | -36.94% | 0.00% |
| SRPT | 0.03% | $10.18B | +26.81% | 0.00% |
| RYN | -0.04% | $4.48B | -2.31% | 3.80% |
| IBRX | -0.04% | $3.73B | +43.05% | 0.00% |
| LOGI | 0.05% | $11.51B | -9.19% | 1.76% |
| SSTI | 0.05% | $148.04M | -50.92% | 0.00% |
| GOLF | -0.05% | $4.21B | +20.68% | 1.22% |
| MGEE | -0.05% | $3.78B | +41.56% | 1.66% |
| BCE | 0.05% | $24.91B | -30.63% | 10.69% |
| CASI | 0.05% | $71.56M | -6.32% | 0.00% |
| AFYA | 0.05% | $1.47B | -16.48% | 0.00% |
| CSR | -0.06% | $1.22B | +37.00% | 4.09% |
| AUDC | -0.06% | $262.07M | -18.71% | 4.14% |
| HLIT | -0.07% | $1.42B | +12.53% | 0.00% |
| RRGB | -0.07% | $82.67M | -42.73% | 0.00% |
| TMDX | 0.08% | $2.78B | +22.14% | 0.00% |
| ESS | -0.08% | $19.39B | +41.91% | 3.22% |
| INFY | 0.09% | $90.23B | +24.60% | 2.66% |
| SMR | 0.09% | $2.73B | +989.52% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CHD | -17.62% | $27.18B | +19.50% | 1.03% |
| AMT | -17.02% | $94.00B | +1.83% | 3.29% |
| CL | -15.44% | $76.48B | +22.25% | 2.12% |
| CMBT | -14.84% | $2.46B | -29.63% | 13.05% |
| FTNT | -14.83% | $69.59B | +72.67% | 0.00% |
| ALNY | -13.57% | $30.22B | +43.13% | 0.00% |
| ETON | -13.43% | $271.28M | +195.77% | 0.00% |
| STG | -13.32% | $35.67M | +7.92% | 0.00% |
| OHI | -12.91% | $10.84B | +26.02% | 6.71% |
| KT | -11.97% | $7.55B | +19.08% | 6.85% |
| COKE | -11.84% | $10.72B | +73.12% | 0.33% |
| AZN | -11.70% | $197.82B | -0.75% | 2.33% |
| VSTO | -11.49% | $2.58B | +71.61% | 0.00% |
| CCI | -11.45% | $45.40B | +0.84% | 6.02% |
| IRDM | -10.95% | $3.11B | -25.13% | 1.97% |
| SYRS | -10.85% | $7.43M | -90.46% | 0.00% |
| ABT | -10.31% | $203.16B | +14.93% | 1.88% |
| ENR | -10.24% | $2.67B | +21.02% | 3.21% |
| PG | -9.91% | $402.15B | +14.14% | 2.33% |
| HIHO | -9.76% | $8.63M | 0.00% | 6.12% |
ETF's related to CRVO
News
Finnhub
CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates - Reported last patient, last visit in its RewinD-LB Phase 2b clinical trial evaluating...
Yahoo
New hires in key scientific and regulatory roles to advance continued development of neflamapimodBOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today reported two senior leadership appointments to advance continued development of neflamapimod. Claudia Ordonez, MD, joined CervoMed as Senior Vice President, Medical Science in October 2024. Dr. Ordonez was previously Chief Medica
Yahoo
- Reported last patient, last visit in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with early-stage dementia with Lewy bodies (DLB) in October 2024; topline data expected in December 2024 – - Hosted a virtual key opinion leader event in July 2024 highlighting neflamapimod’s potential for patients with early-stage DLB – BOSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neu
Finnhub
BOSTON - CervoMed Inc. , a clinical-stage company focused on developing treatments for age-related neurologic disorders, announced today it was awarded by the Galien Foundation the Prix Galien USA...
Yahoo
BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that the Company’s Management will participate in the following investor conferences during the month of November: Sidoti Virtual Micro Cap ConferenceFormat: Corporate presentation Date: Thursday, November 14, 2024Time: 2:30 PM ETWebcast Link: click here Stifel 2024 Healthcare ConferenceFormat: Corporate presentati
Finnhub
BOSTON - CervoMed Inc. , a clinical-stage company focused on developing treatments for age-related neurologic disorders, today announced key takeaways from two oral presentations characterizing the...
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.